Otsuka Gains FDA Advisory Committee Review of Brexpiprazole sNDA for PTSD Combination Indication

A scheduled Psychopharmacologic Drugs Advisory Committee (PDAC) review of Otsuka Pharmaceutical's brexpiprazole sNDA signals a meaningful inflection point for regulatory affairs teams managing combination-therapy indication expansions. The committee convenes on July 18, 2025, at FDA's White Oak Campus in Silver Spring, MD, to evaluate supplemental New Drug Application 205422/S-012 for REXULTI (brexpiprazole) tablets in the treatment of adults with post-traumatic stress disorder, used in combination with sertraline.

The combination-therapy framing is the operative detail for regulatory leads. Brexpiprazole is already approved as an adjunctive therapy for major depressive disorder and for agitation associated with Alzheimer's dementia; this sNDA extends the label into a distinct psychiatric indication requiring co-administration with a specific agent. That construct raises layered questions around efficacy attribution, trial design adequacy, and labeling precision, precisely the territory where AdCom panels apply the closest scrutiny.

For teams benchmarking their own sNDA strategies, the PDAC's line of questioning on July 18 will be instructive. Advisory committees provide non-binding recommendations, and FDA is not legally obligated to follow them, but the agency's historical alignment with PDAC guidance makes the panel's vote a reliable leading indicator of the final regulatory outcome. Background materials, including FDA's briefing document and Otsuka's submission summary, are expected to be posted publicly no later than two business days before the meeting, a narrow window that rewards early monitoring.

Public participation remains open through the docket. Comments submitted to FDA-2025-N-1450 by July 3, 2025 will be provided directly to the committee; submissions received between July 4 and the docket close date of July 17, 2025 will be taken into consideration by FDA but may not reach panelists before deliberation. Regulatory affairs teams with data or scientific perspectives relevant to the brexpiprazole PTSD indication should plan submissions accordingly. The meeting will be broadcast live via YouTube and through FDA's online conferencing platform, with captioning and recording available.

The committee's vote on the benefit-risk profile of brexpiprazole for PTSD in combination with sertraline will establish a visible precedent for how PDAC evaluates adjunctive psychiatric indications where the comparator arm and the combination partner are both active agents.

Source: U.S. Food and Drug Administration, Advisory Committee Calendar via FDA.gov, published June 24, 2025. Meeting scheduled July 18, 2025, 9:00 a.m. – 4:00 p.m. ET; live webcast available via FDA YouTube channel.